Holen Sie sich die Stockscreener-App
9.05
4.50%
0.39
Vorhandelsmarkt:
8.80
-0.25
-2.76%
Schlusskurs vom Vortag:
$8.66
Offen:
$8.61
24-Stunden-Volumen:
695.59K
Relative Volume:
0.85
Marktkapitalisierung:
$538.87M
Einnahmen:
$8.78M
Nettoeinkommen (Verlust:
$-104.70M
KGV:
-3.8186
EPS:
-2.37
Netto-Cashflow:
$-82.68M
1W Leistung:
-8.31%
1M Leistung:
+53.39%
6M Leistung:
-34.80%
1J Leistung:
-21.98%
1-Tages-Spanne:
$8.51
$9.24
1-Wochen-Bereich:
$8.30
$10.12
52-Wochen-Spanne:
$5.35
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie STOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
9.05 | 538.87M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.60 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.67 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
569.12 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.35 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
235.94 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Invesco Ltd. Takes Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
JPMorgan Chase & Co. Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Monday - Defense World
Technical analysis of Stoke Therapeutics Inc (STOK) stock chart patterns - uspostnews.com
Biogen tops estimates on rare disease strength, cuts full-year guidance - The Pharma Letter
Biogen lowers annual earnings outlook, surpasses Q1 estimates By Investing.com - Investing.com Canada
Legal & General Group Plc Decreases Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Market Momentum Report: Stoke Therapeutics Inc (STOK)’s Negative Close at 9.47 - DWinneX
Renaissance Technologies LLC Invests $1.42 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Market Highlights: Stoke Therapeutics Inc (STOK) Ends on a High Note at 9.52 - DWinneX
Stoke Therapeutics Inc (STOK) deserves deeper analysis - uspostnews.com
Geode Capital Management LLC Purchases 6,264 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock? - MSN
Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock? - NewsBreak: Local News & Alerts
Stoke Therapeutics Inc (STOK) rating initates by Chardan Capital Markets - knoxdaily.com
(STOK) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Leerink Partnrs Issues Optimistic Estimate for STOK Earnings - Defense World
Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be - simplywall.st
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of “Buy” by Analysts - Defense World
Vanguard Group Inc. Sells 28,049 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Wellington Management Group LLP Has $1.49 Million Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Needham & Company LLC Reiterates Buy Rating for Stoke Therapeutics (NASDAQ:STOK) - Defense World
Needham Keeps Their Buy Rating on Stoke Therapeutics (STOK) - The Globe and Mail
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - simplywall.st
Stoke Therapeutics stock hits 52-week low at $6.09 amid market challenges By Investing.com - Investing.com South Africa
Stoke Therapeutics stock hits 52-week low at $6.09 amid market challenges - Investing.com India
Teacher Retirement System of Texas Purchases Shares of 10,219 Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - Business Wire
Revolutionary RNA Treatment for Rare Disease: Stoke CEO to Reveal Latest Progress - Stock Titan
Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential - TradingView
Swiss National Bank Acquires 11,400 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
FY2025 Earnings Forecast for STOK Issued By Chardan Capital - Defense World
Charles Schwab Investment Management Inc. Grows Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges By Investing.com - Investing.com South Africa
Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges - Investing.com Australia
Dravet Syndrome Market Expected to Experience Major Growth - openPR.com
Bank of New York Mellon Corp Acquires 1,330 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
(STOK) Technical Data - news.stocktradersdaily.com
Cantor Fitzgerald Issues Positive Forecast for STOK Earnings - Defense World
Wedbush Equities Analysts Raise Earnings Estimates for STOK - Armenian Reporter
Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Brokers Offer Predictions for STOK Q3 Earnings - Defense World
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.73%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):